Form 4: Replimune CCO Sells 12,000 Shares via 10b5-1 Plan

Replimune Group Chief Commercial Officer Christopher Sarchi sold 12,000 shares of common stock at a weighted average price of $9.24.

Summary

• Christopher Sarchi, Chief Commercial Officer of Replimune Group, Inc., executed a sale of 12,000 shares of common stock.
• The transaction occurred on June 1, 2026, at a weighted average price of $9.24 per share.
• The sale was conducted under a pre-established Rule 10b5-1 trading plan adopted on December 15, 2025.
• Following the transaction, the reporting person retains beneficial ownership of 180,962 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was conducted through a pre-planned, automated trading program.

Positives

• The sale was executed pursuant to a pre-planned Rule 10b5-1 trading plan, which is a standard mechanism for executives to sell shares without triggering concerns regarding insider information.

Negatives

• The transaction represents a reduction in the executive's direct equity stake in the company.

Risks

• Market perception of insider selling can sometimes lead to short-term downward pressure on the stock price.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Management Comments

• The reporting person confirmed the sale was made pursuant to a Rule 10b5-1 trading plan adopted on December 15, 2025.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is common in the biotechnology sector and is generally viewed as a standard liquidity event for executives rather than a signal of company performance.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate officers to manage equity holdings while maintaining compliance with SEC regulations.

Stakeholder Impact

• Minimal impact expected as the sale was pre-planned and represents a small portion of the executive's total holdings.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Replimune, REPL, Insider Trading, Form 4, Biotech, Christopher Sarchi